Transgene will present preclinical data on its PoxSTG-EEV virus at SITC
The Strasbourg-based biotech company indicated, in a press release published on October 5, 2026, that it will exhibit preclinical data on a chimeric oncolytic poxvirus designed for systemic administration. The program is upstream of its clinical assets and extends the group's research focus on a new generation of oncolytic viruses.
Presentation on November 7, 2026 at the Phoenix Congress
Transgene announced the presentation of a poster dedicated to PoxSTG-EEV, presented as an enveloped oncolytic virus, at the annual meeting of the Society for Immunotherapy of Cancer (SITC). The congress will be held from November 4 to 8, 2026 in Phoenix, Arizona.
The poster, entitled "PoxSTG-EEV: a Novel Enveloped Virion-Based Formulation of a Chimeric Oncolytic PoxVirus Adapted for Systemic Delivery", bears abstract number 1050 and will be presented on November 7, 2026. It is signed in particular by Johann Foloppe and Philippe Erbs, alongside six other authors.
The abstract will be posted on the SITC website on November 3, 2026, at 9 a.m. (Eastern Time).
A preclinical asset distinct from the Myvac and BT-001 programs
PoxSTG-EEV falls under the discovery and preclinical research work conducted by Transgene. It is distinct from the group's clinical assets: TG4050, the company's first individualized therapeutic vaccine resulting from the Myvac platform and the company's lead asset, TG4070, in Phase 1 in combination with nivolumab in non-small cell lung cancer, and BT-001, an oncolytic virus based on the Invir.IO platform and in clinical development.
The company leverages its expertise in viral vector engineering to design a new generation of multifunctional oncolytic viruses. In the disclaimers accompanying the press release, Transgene reminds that positive preclinical data may not be predictive of clinical results in humans.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
SectorPharmacie et biotechnologies›Biotechnologies
Context
Period
Period: 9M 2026
Guidance from the release
Under current plans, the company has sufficient cash to ensure financial visibility until early 2028
Risks mentioned
L'activité repose sur le succès de essais cliniques en phase 1/2 pour TG4050 et TG4070, avec résultats finaux attendus fin Q1 2028
La dépendance à l'égard du crédit d'impôt recherche (CIR) : €3,9 M sur €4,3 M d'operating income, soit 91% de ce résultat
Consommation de trésorerie continue : €29,5 M en 9 mois 2026, limitant la visibilité au-delà de début 2028
Opportunities identified
Publication positive de TG4050 dans Nature Communications confirmant 100% DFS après 3+ ans, validant le modèle clinique
Expansion de la plateforme myvac® avec lancement de TG4070 en phase 1 combinée nivolumab dans le poumon (NSCLC)
Capacités de production en phase 3 prêtes fin 2027 et clarté financière jusqu'à début 2028 pour financer les développements
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.